Bayer announced last week that the UK’s MHRA has authorised its 52mg levonorgestrel releasing intrauterine system Mirena for extended use up to eight years for contraception in the UK.
Novartis recently announced that it has received approval from the US FDA for commercial manufacturing of Pluvicto at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States.
Mohammed Samy, Head of Supply Chain at Pharmanovia looks to answer the question how can we future proof value chains to build resilience and agility without compromising our ESG efforts?
Eli Lilly and Company have announced LillyDirect, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes.
Junior Doctors across the NHS are beginning a new, and record-breaking round of strikes as they search for an increase to their wages in-line with UK inflation. We at EPM explore why they are striking, and the impact it is likely to have.
Aquaria is the name of the new machine engineered and manufactured within the IMA Group's Active division for washing of components and parts of solid pharmaceutical production and packaging lines.
Ahead of the Pharmapack Europe we at EPM HQ caught up with Windgap Medical, a start-up pioneering several drug delivery innovations, including a proprietary two-chamber autoinjector that hopes to solve many of the present formulation challenges.
As we move into 2024, life sciences real estate managers will need to consider sustainability, funding, investor consolidation, and planning regulations as top priorities.
Shionogi B.V., the European subsidiary of SHIONOGI & Co., Ltd. have announced that they have signed a distribution agreement with Swedish Orphan Biovitrum AB, Sobi, for Fetcroja covering 13 countries in Central & Eastern Europe.
As we close off this year at EPM, we look back at one of our standout interviews with Alison Dillon, Director of Marketing Communications and Strategy at Sharp.
Organon have announced an agreement with Eli Lilly and Company to become the sole distributor and promoter for the migraine medicines Emgality (galcanezumab) and RAYVOW (lasmiditan) in Europe.
